<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04409964</url>
  </required_header>
  <id_info>
    <org_study_id>OFGA</org_study_id>
    <nct_id>NCT04409964</nct_id>
  </id_info>
  <brief_title>the Effect of Opioid-free General Anesthesia</brief_title>
  <official_title>the Effect of Opioid-free General Anesthesia on the Recovery Quality After Gynecological Laparoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Catholic University of Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is performed to investigate the effect of opioid-free general anesthesia on the
      recovery quality after gynecological laparoscopy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The quality of recovery after the surgery is assessed using the QoR 40. In addition, the
      various kinds of cytokine are assessed for the ancillary study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the quality of recovery</measure>
    <time_frame>at 24 hour after the completion of surgery</time_frame>
    <description>The quality of recovery is assessed using questionnaire. This questionnaire includes 40 items. The score range is from 40 to 200. The higher score means the better quality of recovery after surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cytokine</measure>
    <time_frame>during surgery</time_frame>
    <description>as ancillary study, to assess the various kinds of cytokines such as epinephrine, norepinephrine, interleukin-10, tumor necrosis factor-alpha.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Gynecologic Disease</condition>
  <arm_group>
    <arm_group_label>opioid-free anesthesia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study group receives the dexmedetomidine and lidocaine infusion with general anesthesia for gynecological laparoscopy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>opioid anesthesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control group receives the remifentanil infusion with general anesthesia for gynecological laparoscopy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine Hydrochloride</intervention_name>
    <description>dexmedetomidine iv bolus followed by the infusion of 0.1-1 ug/kg/hr during general anesthesia</description>
    <arm_group_label>opioid-free anesthesia</arm_group_label>
    <other_name>precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine Hydrochloride</intervention_name>
    <description>lidocaine iv bolus followed by the infusion of 1.5 mg/kg/hr during general anesthesia</description>
    <arm_group_label>opioid-free anesthesia</arm_group_label>
    <other_name>lidocaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil Hydrochloride</intervention_name>
    <description>remifentanil iv infusion of 0.5-5 ng/ml (effect site concentration using TCI) during general anesthesia</description>
    <arm_group_label>opioid anesthesia</arm_group_label>
    <other_name>remifentanil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient scheduled for gynecological laparoscopic surgery

        Exclusion Criteria:

          1. refusal to participate in this study

          2. emergent surgery

          3. chronic pain requiring for pain killer

          4. psychiatric disease

          5. preoperative bradycardia or hypotension

          6. allergy or history of the adverse effect to study drug

          7. pregnancy or lactation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>the patients undergoing the gynecological laparoscopic surgery</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Youngeun Moon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul St. Mary's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Youngeun Moon, MD</last_name>
    <phone>822-2258-6163</phone>
    <email>0910momo@naver.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hun Choi, MD</last_name>
    <phone>822-2258-2263</phone>
    <email>cmcanepm@catholic.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul St.Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seocho-gu</state>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hun Choi, MD</last_name>
      <phone>+82222586163</phone>
      <email>momo0910@hanmail.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul St.Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seocho-gu</state>
        <zip>07651</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hun Choi, MD</last_name>
      <phone>82222586163</phone>
      <email>momo0910@daum.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 26, 2020</study_first_submitted>
  <study_first_submitted_qc>May 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2020</study_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Catholic University of Korea</investigator_affiliation>
    <investigator_full_name>Young Eun Moon</investigator_full_name>
    <investigator_title>associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Genital Diseases, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

